The type 2 inflammatory response is induced by various environmental and infectious stimuli. Although recent studies identified group 2 innate lymphoid cells (ILC2s) as potent sources of type 2 cytokines, the molecular pathways controlling ILC2 responses are incompletely defined. Here we demonstrate that murine ILC2s express the b 2 -adrenergic receptor (b 2 AR) and colocalize with adrenergic neurons in the intestine. b 2 AR deficiency resulted in exaggerated ILC2 responses and type 2 inflammation in intestinal and lung tissues. Conversely, b 2 AR agonist treatment was associated with impaired ILC2 responses and reduced inflammation in vivo. Mechanistically, we demonstrate that the b 2 AR pathway is a cell-intrinsic negative regulator of ILC2 responses through inhibition of cell proliferation and effector function. Collectively, these data provide the first evidence of a neuronalderived regulatory circuit that limits ILC2-dependent type 2 inflammation.
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The type 2 inflammatory response is induced by various environmental and infectious stimuli. Although recent studies identified group 2 innate lymphoid cells (ILC2s) as potent sources of type 2 cytokines, the molecular pathways controlling ILC2 responses are incompletely defined. Here we demonstrate that murine ILC2s express the b 2 -adrenergic receptor (b 2 AR) and colocalize with adrenergic neurons in the intestine. b 2 AR deficiency resulted in exaggerated ILC2 responses and type 2 inflammation in intestinal and lung tissues. Conversely, b 2 AR agonist treatment was associated with impaired ILC2 responses and reduced inflammation in vivo. Mechanistically, we demonstrate that the b 2 AR pathway is a cell-intrinsic negative regulator of ILC2 responses through inhibition of cell proliferation and effector function. Collectively, these data provide the first evidence of a neuronalderived regulatory circuit that limits ILC2-dependent type 2 inflammation.
T he type 2 inflammatory response is a highly conserved module of the innate and adaptive immune system that is elicited after exposure to infectious and environmental triggers, such as helminth infections, allergens, venoms, and other stimuli (1) (2) (3) . The hallmarks of type 2 responses include activation of T helper 2 (T H 2) cells and release of type 2 cytokines, such as interleukin-4 (IL-4), IL-5, IL-9, and IL-13; production of immunoglobulin E (IgE); and the activation of multiple effector cells, such as basophils, mast cells, and eosinophils. This cascade of immunologic events is associated with increased mucus production from goblet cells and induction of smooth-muscle contractility that contributes to the elimination of pathogens or allergic stimuli (4, 5) . Recent studies identified group 2 innate lymphoid cells (ILC2s) as a potent source of type 2 cytokines that contribute to the type 2 inflammatory responses (5) (6) (7) (8) (9) (10) (11) . Although considerable advances have been made to define the cytokines, growth factors, and environmental stimuli that trigger ILC2 responses, the regulatory mechanisms that constrain ILC2 responses and type 2 inflammation at mucosal sites remain incompletely understood.
Mucosal and lymphoid tissues are highly innervated (12) (13) (14) , and immune cells-including mast cells, macrophages, ILCs, and T cells-can be regulated by neuronal-derived bioactive molecules in certain circumstances (15) (16) (17) (18) (19) (20) (21) (22) (23) . However, our knowledge of the complex interactions between the nervous system and ILCs in the context of type 2 inflammation is still limited. RNA sequencing (RNA-seq) of sorted murine ILC subsets revealed that small intestinal (SI) ILC2s exhibited higher levels of the b 2 AR gene (Adrb2) mRNA expression compared to SI ILC3s, but lower levels of other adrenergic receptors (Fig. 1A) . Consistent with these results, ILC2s sorted from SI lamina propria (SILP), gut-draining mesenteric lymph node (mLN), colon LP, and lung exhibited higher levels of Adrb2 mRNA expression compared to SILP ILC3s (Fig. 1B and fig. S1A ). ILC2s from mesenteric white adipose tissue exhibited lower levels of Adrb2 mRNA expression compared to ILC2s from other tissue. We also detected ADRB2 mRNA in ILC2s and CD4 + T cells sorted from human lung and peripheral blood mononuclear cells (Fig. 1C) . These results show that the b 2 AR gene is expressed in murine and human ILC2s.
Examination of the localization of ILC2s (defined as KLRG1
) and adrenergic neurons [marked by tyrosine hydroxylase (TH) expression] in the SI microenvironment revealed that ILC2s were found in close proximity to TH + neurons in the villi and submucosa but not in the muscularis (Fig. 1, D (Fig. 1F and fig. S1 , C and D). Notably, the highest expression levels of genes encoding enzymes involved in norepinephrine synthesis, Th and Dbh (dopamine b-hydroxylase), were found in the parenchyma fraction in the SI (Fig. 1, G and H) , which collectively suggests that ILC2s may respond to neuronal-derived norepinephrine, a b 2 AR ligand. ILC2s were also observed in the interfollicular region (24) , paracortical region, and the medulla of the draining mLN, which are anatomical sites where sympathetic adrenergic neurons are abundant (12, 13) (Fig. 1, I (25) in the bone marrow (BM, fig. S2A ). Additionally, Adrb2
+/+ and Adrb2 −/− mice had similar frequencies of all ILC subsets in mLNs and in SILP ( fig. S2 , B to D), indicating that b 2 AR deficiency does not result in impaired ILC2 development or homeostasis at steady state.
Next, we examined whether b 2 AR signaling regulates ILC2 responses and type 2 inflammation after exposure to the gastrointestinal helminth Nippostrongylus brasiliensis. This infection induces potent ILC2 responses that play an important role in the expulsion of the parasite through production of IL-5 and IL-13 (10, 26, 27 fig. S2I) , b 2 AR agonist-treated wild-type C57BL/6 (B6) mice exhibited significantly fewer ILC2s in the mLNs compared to vehicle-treated mice after N. brasiliensis infection (Fig. 2F) . Further, agonist treatment was associated with significantly fewer IL-5-and IL-13-producing ILC2s, reduced eosinophilia, and diminished goblet cell responses (Fig. 2, G  to I, and fig. S2J ). Consistent with these results, agonist-treated mice had significantly higher worm burdens (Fig. 2J) . We also treated the mice with another b 2 AR agonist, salmeterol, during N. brasiliensis infection and found reduced anti-helminth responses ( fig. S2K ), indicating that both b 2 AR agonists have an inhibitory effect on type 2 inflammation.
Because type 2 cytokine production from ILC2s was reduced after simultaneous exposure to a b 2 AR agonist and helminth infection in vivo ( Fig. 2G and fig. S2J ), we next sought to test whether ILC2 effector function is regulated by short-term b 2 AR stimulation in vitro. SILP cells from Il13-YFP (yellow fluorescent protein) reporter mice were cultured with IL-33 for 4 hours in the presence of a b 2 AR agonist or control vehicle. Agonist-treated cells exhibited lower frequencies of YFP-expressing ILC2s compared to vehicle-treated controls ( fig. S2L ), suggesting that signaling through b 2 AR negatively regulates acute activation and IL-13 production from ILC2s.
In addition to ILC2s, b 2 AR agonists can alter the T H 1/T H 2 cell balance by inhibiting the development of T H 1 cells (28) . Therefore, we examined whether b 2 AR stimulation by the agonist could inhibit ILC2 responses and inflammation in the absence of CD4 + T cells. After treatment of B6 mice with a CD4-depleting monoclonal antibody (mAb) and the b 2 AR agonist, fewer ILC2s were observed after N. brasiliensis infection than were observed in vehicle-treated mice (Fig. 2K) . Additionally, mice treated with both anti-CD4 mAb and agonist exhibited fewer cytokine-producing ILC2s and increased worm burdens compared to vehicle-treated mice ( worm burdens compared to control Il7r cre/+ mice (Fig. 2, N and O) Because lung ILC2s exhibited high levels of Adrb2 mRNA expression (Fig. 1B) and lung tissue is also highly innervated (15, 19) , we examined if b 2 AR signaling controls ILC2 responses in the lung as it does in the intestine. After inoculation, N. brasiliensis larvae migrate to and induce inflammation in the lung before reaching the intestine. Adrb2 −/− mice exhibited increased frequencies of ILC2s in the lung compared to Adrb2 +/+ mice after infection (Fig. 3A) . As an additional approach to induce lung inflammation, we administered the alarmin IL-33 intranasally and observed increased frequencies of ILC2s in Adrb2 −/− mice compared to that in Adrb2 +/+ mice (Fig. 3B) . Further, ILC2 frequencies and cytokine production after IL-33 administration were inhibited by b 2 AR agonist treatment (Fig. 3,  C and D) . Similarly, when the mice received extract of the fungal allergen Alternaria alternata intranasally, b 2 AR agonist-treated mice had reduced frequencies of ILC2s in the lungs than did vehicle-treated mice (Fig. 3E ). In addition, Il7r cre/+ Adrb2 f/f mice exhibited increased ILC2 frequencies and cytokine production compared to Il7r cre/+ mice after the Alternaria extract administration together with anti-CD4 mAb treatment (Fig. 3, F and G) . Collectively, these results indicate that b 2 AR signaling is an evolutionarily conserved regulatory pathway serving to dampen ILC2 responses against diverse inflammatory stimuli at multiple mucosal barrier surfaces.
These data provoke the hypothesis that the signaling through b 2 AR on ILC2s negatively regulates ILC2 responses and type 2 inflammation after exposure to helminth infection and allergens. To investigate the mechanisms underlying this effect, we performed RNA-seq analysis on ILC2s sorted from N. brasiliensis-infected Adrb2 +/+ mice with or without b 2 AR agonist treatment. Although ILC2s from both groups exhibited similar expression levels of genes encoding ILC2-associated transcription factors (Id2, Gata3, and Rora) and cytokine receptors (Il1rl1, Crlf2, and Il4ra) (Fig. 4A) , we also observed significant downregulation of a number of genes in the agonisttreated groups compared to that in controls. Gene set enrichment analysis (GSEA) of the downregulated genes revealed significant enrichment in gene ontology (GO) terms associated with the cell cycle and cell proliferation (Fig. 4, B and C,  and fig. S3A ). Taken together with the reduced ILC2 numbers observed in these mice after infection (Fig. 2F) , these results collectively suggest a role for b 2 AR signaling in limiting the proliferation and accumulation of ILC2s.
To directly test whether b 2 AR signaling regulates ILC2 proliferation in vivo, we analyzed the expression of the proliferation marker Ki67 during N. brasiliensis infection in mice treated with the b 2 AR agonist. After treatment, ILC2s from these mice exhibited reduced frequencies of Ki67-expressing ILC2s, but comparable frequencies of apoptotic ILC2s, compared to those of vehicletreated control mice after infection (Fig. 4D and  fig. S3B ), suggesting that b 2 AR stimulation suppresses ILC2 proliferation but does not regulate apoptosis. Further, this regulation was not restricted to N. brasiliensis, because it was also observed after infection with another gastrointestinal helminth, Heligmosomoides polygyrus bakeri (Fig. 4E) . In addition, when Adrb2 +/+ and Adrb2 −/− mice were injected with IL-33 intraperitoneally, the frequencies of Ki67 significantly higher in Adrb2 −/− mice than in Adrb2 +/+ mice (Fig. 4F) . Together, these data indicate that b 2 AR signaling negatively regulates ILC2 proliferation in vivo during type 2 inflammation.
To examine whether b 2 AR-dependent inhibition of ILC2 proliferation is cell intrinsic, sorted ILC2s were stained with a proliferation dye (CellTrace Violet) and then cultured in vitro with a b 2 AR agonist. Agonist-treated ILC2s exhibited significantly higher levels of CellTrace Violet intensity compared to vehicle-treated ILC2s, suggesting that the reduced proliferation after b 2 AR agonist treatment occurs through a cellintrinsic mechanism (Fig. 4G) in vivo, we reconstituted irradiated B6 mice with congenically marked Adrb2 +/+ and Adrb2 −/− BM cells and compared the proliferation of Adrb2 +/+ and Adrb2 −/− ILC2s in the same chimeric mouse (Fig. 4H) S2, B to D) . However, after N. brasiliensis infection, the frequencies of Adrb2 −/− ILC2s were increased compared to the frequencies of Adrb2 +/+ ILC2s (Fig. 4H) , indicating that b 2 AR signaling inhibits ILC2 proliferation in a cell-intrinsic manner in vivo.
Collectively, these results reveal a previously unrecognized regulatory circuit that operates between the adrenergic nervous system and the innate immune system to control type 2 inflammation at multiple mucosal sites. Specifically, signaling through b 2 AR negatively regulates ILC2 proliferation and effector function. Given the importance of ILC2s in driving type 2 immune responses (10, 26, 27 ) and the altered b 2 AR expression levels on ILC2s during inflammation, it appears that b 2 AR may function as a molecular rheostat to fine-tune the ILC2 response, thus controlling the balance between promotion of hostprotective acute ILC2 responses and prevention of chronic pathologic type 2 inflammation. Intriguingly, in contrast to the adrenergic-mediated negative regulation observed here, recent studies have identified cholinergic neurons as potent activators of intestinal and lung ILC2s through the production of the neuropeptide neuromedin U (20) (21) (22) . Thus, the mammalian nervous system appears to have evolved dual mechanisms to rapidly activate or repress these innate immune cells to protect the host against diverse inflammatory stimuli.
